Rice University Bioengineer Receives $2.2M Gates Foundation Grant for Revolutionary Long-Acting Cell Factory Implants
核心洞察
Rice University bioengineer Omid Veiseh has secured a $2.2 million grant from the Bill and Melinda Gates Foundation (搜索) to develop implantable cell factory platforms that deliver therapeutic antibodies continuously for two years or longer.
The innovative technology aims to address critical limitations of current monoclonal antibody treatments, which require frequent high-dose injections and create fluctuating drug levels that impact patient adherence and healthcare costs.
Two complementary strategies are being developed: hydrogel capsules for subcutaneous injection targeting seasonal malaria (搜索) prophylaxis, and wireless miniaturized devices for continuous HIV (搜索)-neutralizing antibody production over four years.
Rice University bioengineer Omid Veiseh has been awarded a $2.2 million grant from the Bill and Melinda Gates Foundation (搜索) to develop groundbreaking implantable cell factory platforms capable of delivering therapeutic antibodies continuously for two years or more. This innovative approach promises to revolutionize the treatment and prevention of infectious diseases such as HIV (搜索) and malaria (搜索) by dramatically reducing dosing frequency and expanding access to biologic therapies in resource-limited settings.
Addressing Critical Limitations of Current Antibody Therapies
More than 212 monoclonal antibodies (搜索) are currently approved for clinical use worldwide, reshaping outcomes across autoimmune disease, infectious disease and oncology. However, despite their clinical success, most antibodies are delivered through frequent high-dose injections or intravenous infusions. This approach creates peak-trough drug levels that can impact tolerability and durability of response, while driving significant healthcare costs, infrastructure demands and patient burden.
"This award enables us to advance a next-generation living protein factory technology that we hope will fundamentally change how infectious diseases like malaria (搜索) and HIV (搜索) are prevented and treated," said Veiseh, who is also a Cancer Prevention and Research Institute of Texas (CPRIT) Scholar and faculty director of the Rice Biotech Launch Pad (搜索).
Building on Proven Preclinical Success
The project, titled "Cell Factories for Durable Protein Expression," builds on progress made under prior support from the Gates Foundation. Earlier studies demonstrated that combining high-potency engineered cell lines with an innovative immunomodulatory hydrogel matrix allowed stable, year-long in vivo production of HIV-neutralizing antibodies (搜索) in preclinical models. This breakthrough validated the concept of implantable living factories and provided crucial insights into biocompatibility and immune response modulation necessary for device longevity and efficacy.
Dual-Strategy Technological Approach
Veiseh and his collaborators, including Michael Diehl from Northwestern University and researchers from Tulane University, have developed two complementary strategies to overcome oxygenation and scalability limitations observed in earlier implantable formats:
Hydrogel Capsule Technology
The first approach employs hydrogel capsules embedded with genetically engineered cells capable of producing antibodies. These soft, biocompatible capsules can be administered through simple subcutaneous injections, making them attractive for scalable preventive interventions such as seasonal malaria (搜索) prophylaxis and treatment.
Wireless Miniaturized Devices
The second strategy involves wireless miniaturized biocompatible devices designed to support continuous antibody production for periods extending beyond four years. These sophisticated devices integrate bioengineering and microelectronics, allowing stable housing and nourishment of living cell factories while enabling potential remote control and monitoring capabilities for chronic disease management involving HIV (搜索).
Global Health Impact and Accessibility
The sustained delivery systems stand to dramatically shift clinical paradigms by maintaining constant drug levels, alleviating the burden of dosing schedules on patients and healthcare systems while improving therapeutic outcomes through continuous pathogen neutralization. This approach is particularly pertinent for infectious diseases prevalent in low- and middle-income countries, where healthcare infrastructure limitations hinder frequent dosing regimens and adherence.
In alignment with the Gates Foundation's Global Access commitment, the project prioritizes scalable manufacturing strategies and cost-of-goods analyses to ensure resulting technologies can be made broadly available at affordable cost to populations most in need.
Broader Therapeutic Applications
Beyond infectious diseases, the technology's modularity permits adaptation toward oncology and autoimmune disorders, where monoclonal antibodies (搜索) also play transformative roles. The potential to embed living protein factories for long-term therapeutic production offers a paradigm shift in biologic drug delivery, enhancing efficacy, patient compliance, and accessibility on a global scale.
Translational Infrastructure Support
Rice University's translational ecosystem, epitomized by the Rice Biotech Launch Pad (搜索) accelerator, provides robust infrastructure for rapid development and commercialization. This environment facilitates bridging the gap between bench science and clinical application, promoting breakthroughs that can swiftly enter the healthcare market to benefit patients worldwide.
The collaboration spanning multiple institutions underscores the necessity of converging expertise in synthetic biology, immunology, and materials science. This integrated approach ensures comprehensive addressing of challenges such as oxygenation within implants, immune evasion, and device scalability—all critical factors for clinical translation.
If successful, Veiseh's living protein factories could inaugurate a new era in the treatment and prevention of chronic and infectious diseases worldwide, potentially reducing health disparities caused by limited access to advanced biologics.